A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Clinical trial NCT02203032 · COMPLETED
Trial details
- NCT number
- NCT02203032
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-07
- Primary completion
- 2015-12-25
- Enrollment
- 872
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.